Kinetic of Compounds of a Melatonin-based Formulation in Healthy Subjects
Not Applicable
Completed
- Conditions
- Melatonin Bioavailability
- Interventions
- Dietary Supplement: dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
- Registration Number
- NCT05419466
- Lead Sponsor
- Larena SAS
- Brief Summary
This study is conducted to clinically document the melatonin and zinc bioavailability of a dietary supplement containing delayed release melatonin, zinc and lemon balm
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 14
Inclusion Criteria
- Male between the ages of 18 and 45,
- In good general health, i.e., free of chronic conditions and not taking medication at the time of inclusion and/or long-term,
- Over 70 kg and with a body mass index between 18.5 and 24.9,
- Able and willing to participate in the research by complying with the procedures of the protocol, in particular concerning the taking of the product under study and the performance of sequential blood tests,
- Having freely signed the consent form after adequate information on the proposed study,
- Affiliated to a social security scheme or similar.
Exclusion Criteria
- Smoker,
- Drug addict,
- Subject with an alcohol consumption of more than 2 glasses per day,
- Taking a drug treatment or melatonin or zinc or a product containing it within 48 hours prior to a kinetics visit,
- Known organic or functional abnormality of the urinary tree,
- Any medical condition that would involve a change in melatonin metabolism: Drug intake: Fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, carbamazepine, rifampicin, analgesics, Liver abnormality known or detected at the screening visit and judged to be clinically significant by the investigator, Known autoimmune disease,
- Any condition that could involve zinc deficiency or hyperzincemia: Medication intake: penicillamine or diuretics, Poisoning by exposure to zinc (zinc mines, zinc metallurgy, galvanizing operations, manufacture of alloys, use of zinc-based pigments and salts, etc.), Pick's disease, malabsorption (pancreatic insufficiency, biliary obstruction, gastrectomy, jejuno-ileostomy, intestinal diverticulum, tropical sprue, celiac disease, cystic fibrosis), intestinal inflammation (enteropathy with protein leakage, inflammatory colitis), liver disorders (cirrhosis, hepatitis) , kidney disorders (chronic renal failure, nephrotic syndrome), neuropsychiatric disorders (anorexia nervosa, endogenous depression, alcoholism), genetic diseases (acrodermatitis enteropathica, thalassemia, sickle cell disease, diabetes, trisomy 21, phenylketonuria), parasitic diseases (ankylostomiasis, schistosomiasis, malaria , giardiasis)
- Subject assessed as "rather" or "definitely" among evening people,
- Epileptic subject,
- Asthmatic subject,
- Known hypertension (>140/90),
- Diagnosis of migraine by a health professional according to the International Headache Society (IHS) criteria revised in 2004,
- With a sleep disorder,
- Thyroid dysfunction, hyperglycemia or anemia judged to be clinically significant by the investigator,
- Blood donation within one month prior to inclusion,
- A known organic or psychological abnormality (including a history of severe depression) that may bias the results of the study as judged by the investigator,
- Workers with atypical working hours (night work, staggered working hours),
- Known allergy or intolerance to any of the components of the product,
- Psychological or linguistic inability to understand and sign informed consent,
- Participant in another interventional clinical trial or during a period of exclusion from a previous clinical trial,
- Under legal protection (guardianship, curatorship) or deprived of his rights as a result of the administrative or judicial decision,
- Subject who has reached the maximum threshold for compensation for research provided for in the regulations.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description melatonin and zinc bioavailability dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm dietary supplement, 1 tablet containing delayed release melatonin, zinc and lemon balm
- Primary Outcome Measures
Name Time Method Evolution of the plasma melatonin concentration Up to 720 minutes after taking the tablet The change in plasma melatonin concentration
- Secondary Outcome Measures
Name Time Method Plasma 6-sulfatoxymelatonin AUC Up to 720 minutes after taking the tablet Area Under the Curve of plasma 6-sulfatoxymelatonin
Plasma 6-sulfatoxymelatonin Cmax Up to 720 minutes after taking the tablet Peak concentration of plasma 6-sulfatoxymelatonin
Plasma 6-sulfatoxymelatonin half life Up to 720 minutes after taking the tablet Time required for the concentration of plasma 6-sulfatoxymelatonin to decrease to half of its starting dose
Plasma zinc Cmax Up to 720 minutes after taking the tablet Peak concentration of plasma zinc
Evolution of state of drowsiness Up to 720 minutes after taking the tablet The change in (Visual Analog Scale)VAS score, minimum = 0 and maximum = 10 higher score means a worse outcome
Plasma melatonin Tmax Up to 720 minutes after taking the tablet Time take to reach Cmax of plasma melatonin
Plasma melatonin half life Up to 720 minutes after taking the tablet Time required for the concentration of plasma melatonin to decrease to half of its starting dose
Evolution of the plasma concentration of 6-sulfatoxymelatonin Up to 720 minutes after taking the tablet The change in plasma 6-sulfatoxymelatonin concentration
Plasma 6-sulfatoxymelatonin Tmax Up to 720 minutes after taking the tablet Time take to reach Cmax of plasma 6-sulfatoxymelatonin
Evolution of the plasma zinc concentration Up to 720 minutes after taking the tablet The change in plasma zinc concentration
Plasma zinc AUC Up to 720 minutes after taking the tablet Area Under the Curve of plasma zinc
Plasma zinc half life Up to 720 minutes after taking the tablet Time required for the concentration of plasma zinc to decrease to half of its starting dose
Plasma melatonin AUC Up to 720 minutes after taking the tablet Area Under the Curve of plasma melatonin
Plasma melatonin Cmax Up to 720 minutes after taking the tablet Peak concentration of plasma melatonin
Plasma zinc Tmax Up to 720 minutes after taking the tablet Time take to reach Cmax of plasma zinc
Adverse events During study participation, maximum 45 days Number and type of adverse events
Trial Locations
- Locations (1)
Cen Experimental
🇫🇷Dijon, France